NCT06962254 2025-05-08
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Phase 1 Recruiting
Clinical Trials
10 trialsNCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT02303899 2021-01-22
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00402766 2015-11-18
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00253565 2013-04-08
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00159016 2011-04-28
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
Hadassah Medical Organization
Phase 2 Withdrawn
NCT00084513 2010-02-12
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT00551252 2007-10-30
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma
Phase 2 Unknown